Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
Sign Up to like & getrecommendations! Published in 2018 at "Cell"
DOI: 10.1016/j.cell.2018.07.009
Abstract: Cancer immunotherapies have shown substantial clinical activity for a subset of patients with epithelial cancers. Still, technological platforms to study cancer T-cell interactions for individual patients and understand determinants of responsiveness are presently lacking. Here,… read more here.
Keywords: tumor; tumor organoids; reactive cells; peripheral blood ... See more keywords
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors
Sign Up to like & getrecommendations! Published in 2022 at "Cell"
DOI: 10.1016/j.cell.2022.02.012
Abstract: The tumor microenvironment hosts antibody-secreting cells (ASCs) associated with a favorable prognosis in several types of cancer. Patient-derived antibodies have diagnostic and therapeutic potential; yet, it remains unclear how antibodies gain autoreactivity and target tumors.… read more here.
Keywords: tumor; evolve non; reactive antibodies; tumor reactive ... See more keywords
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
Sign Up to like & getrecommendations! Published in 2021 at "Nature Communications"
DOI: 10.1038/s41467-021-21241-0
Abstract: T cell rejuvenation by PD-1/PD-L1 blockade, despite emerging as a highly promising therapy for advanced cancers, is only beneficial for a minority of treated patients. There is evidence that a lack of efficient T cell… read more here.
Keywords: tumor; anti antibody; reactive cells; cell ... See more keywords
Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-45449-y
Abstract: Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most of the research on T cell exhaustion and PD-1 blockade has been focused on conventional αβ T… read more here.
Keywords: blockade; response; cell; reactive cells ... See more keywords
IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-54420-w
Abstract: Blockade of NKG2A/HLA-E interaction is a promising strategy to unleash the anti-tumor response. Yet the role of NKG2A+ CD8 T cells in the anti-tumor response and the regulation of NKG2A expression on human tumor-infiltrating T… read more here.
Keywords: cd8 cells; human tumor; tumor; reactive cd8 ... See more keywords
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms
Sign Up to like & getrecommendations! Published in 2024 at "Nature Biotechnology"
DOI: 10.1038/s41587-024-02232-0
Abstract: A central challenge in developing personalized cancer cell immunotherapy is the identification of tumor-reactive T cell receptors (TCRs). By exploiting the distinct transcriptomic profile of tumor-reactive T cells relative to bystander cells, we build and… read more here.
Keywords: clinically relevant; cell receptors; personalized cell; cell therapy ... See more keywords
Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells.
Sign Up to like & getrecommendations! Published in 2019 at "Biomaterials science"
DOI: 10.1039/c8bm01556b
Abstract: Interleukin-2 (IL-2) is a potent T-cell mitogen that can adjuvant anti-cancer adoptive T-cell transfer (ACT) immunotherapy by promoting T-cell engraftment. However, the clinical applications of IL-2 in combination with ACT are greatly hindered by the… read more here.
Keywords: tumor; redox responsive; reactive cells; cell ... See more keywords
Frequency determination of breast tumor-reactive CD4 and CD8 T cells in humans: unveiling the antitumor immune response
Sign Up to like & getrecommendations! Published in 2019 at "OncoImmunology"
DOI: 10.1080/2162402x.2019.1607674
Abstract: ABSTRACT As cancer immunotherapy gains importance, the determination of a patient’s ability to react to his/her tumor is unquestionably relevant. Though the presence of T cells that recognize specific tumor antigens is well established, the… read more here.
Keywords: frequency; tumor reactive; reactive cells; tumor ... See more keywords
Bone marrow expands the repertoire of functional T cells targeting tumor-associated antigens in patients with resectable non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Oncoimmunology"
DOI: 10.1080/2162402x.2019.1671762
Abstract: ABSTRACT The efficacy of cancer immunotherapy may be improved by increasing the number of circulating tumor-reactive T cells. The bone marrow is a priming site and reservoir for such T cells. The characteristics of bone… read more here.
Keywords: reactive cells; bone marrow; tumor; tumor reactive ... See more keywords
Novel stimulation strategy with autologous tumor cells to generate T cell receptor‐engineered T cells in esophageal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13404
Abstract: Esophageal cancer is one of the most common cancers worldwide, associated with more than 400 000 cancerrelated deaths each year. It is a global concern, especially in China. Around 200 000 new cases of esophageal… read more here.
Keywords: tumor; cell receptor; tumor specific; cancer ... See more keywords
PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-16-1692
Abstract: Purpose: Infusion of highly heterogeneous populations of autologous tumor-infiltrating lymphocytes (TIL) can result in tumor regression of exceptional duration. Initial tumor regression has been associated with persistence of tumor-specific TILs 1 month after infusion, but… read more here.
Keywords: tumor; cd8; cd8 cells; reactive cd8 ... See more keywords